Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.
Identifieur interne : 001375 ( PubMed/Corpus ); précédent : 001374; suivant : 001376Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.
Auteurs : Sanjay Mehta ; Bhagavatula Kutumba Srinivasa Sastry ; Rogério Souza ; Adam Torbicki ; Hossein-Ardeschir Ghofrani ; Richard N. Channick ; Marion Delcroix ; Tomás Pulido ; Gérald Simonneau ; John Wlodarczyk ; Lewis J. Rubin ; Pavel Jansa ; Elke Hunsche ; Nazzareno Galiè ; Loïc Perchenet ; Olivier SitbonSource :
- Chest [ 1931-3543 ] ; 2017.
English descriptors
- KwdEn :
- Adult, Dose-Response Relationship, Drug, Drug Monitoring (methods), Endothelin B Receptor Antagonists (administration & dosage), Endothelin B Receptor Antagonists (adverse effects), Female, Humans, Hypertension, Pulmonary (diagnosis), Hypertension, Pulmonary (drug therapy), Hypertension, Pulmonary (physiopathology), Hypertension, Pulmonary (psychology), Male, Middle Aged, Patient Acuity, Pyrimidines (administration & dosage), Pyrimidines (adverse effects), Quality of Life, Sulfonamides (administration & dosage), Sulfonamides (adverse effects), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Endothelin B Receptor Antagonists, Pyrimidines, Sulfonamides.
- chemical , adverse effects : Endothelin B Receptor Antagonists, Pyrimidines, Sulfonamides.
- diagnosis : Hypertension, Pulmonary.
- drug therapy : Hypertension, Pulmonary.
- methods : Drug Monitoring.
- physiopathology : Hypertension, Pulmonary.
- psychology : Hypertension, Pulmonary.
- Adult, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Patient Acuity, Quality of Life, Treatment Outcome.
Abstract
Pulmonary arterial hypertension (PAH) leads to reduced health-related quality of life (HRQoL). The objectives of this analysis were to evaluate the effect of macitentan on HRQoL in patients with PAH in the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome (SERAPHIN) study. The association between baseline HRQoL and long-term outcomes was also investigated.
DOI: 10.1016/j.chest.2016.08.1473
PubMed: 27671974
Links to Exploration step
pubmed:27671974Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.</title><author><name sortKey="Mehta, Sanjay" sort="Mehta, Sanjay" uniqKey="Mehta S" first="Sanjay" last="Mehta">Sanjay Mehta</name><affiliation><nlm:affiliation>London Health Sciences Centre, Victoria Hospital, Western University, London, ON, Canada. Electronic address: sanjay.mehta@lhsc.on.ca.</nlm:affiliation></affiliation></author><author><name sortKey="Sastry, Bhagavatula Kutumba Srinivasa" sort="Sastry, Bhagavatula Kutumba Srinivasa" uniqKey="Sastry B" first="Bhagavatula Kutumba Srinivasa" last="Sastry">Bhagavatula Kutumba Srinivasa Sastry</name><affiliation><nlm:affiliation>CARE Hospitals, Hyderabad, India.</nlm:affiliation></affiliation></author><author><name sortKey="Souza, Rogerio" sort="Souza, Rogerio" uniqKey="Souza R" first="Rogério" last="Souza">Rogério Souza</name><affiliation><nlm:affiliation>Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Torbicki, Adam" sort="Torbicki, Adam" uniqKey="Torbicki A" first="Adam" last="Torbicki">Adam Torbicki</name><affiliation><nlm:affiliation>Centre of Postgraduate Medical Education, Europejskie Centrum Zdrowia, Otwock, Poland.</nlm:affiliation></affiliation></author><author><name sortKey="Ghofrani, Hossein Ardeschir" sort="Ghofrani, Hossein Ardeschir" uniqKey="Ghofrani H" first="Hossein-Ardeschir" last="Ghofrani">Hossein-Ardeschir Ghofrani</name><affiliation><nlm:affiliation>University of Giessen and Marburg Lung Center, Giessen, Germany, Member of the German Center of Lung Research (DZL), Giessen, Germany, and Department of Medicine, Imperial College London, London, England.</nlm:affiliation></affiliation></author><author><name sortKey="Channick, Richard N" sort="Channick, Richard N" uniqKey="Channick R" first="Richard N" last="Channick">Richard N. Channick</name><affiliation><nlm:affiliation>Massachusetts General Hospital, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Delcroix, Marion" sort="Delcroix, Marion" uniqKey="Delcroix M" first="Marion" last="Delcroix">Marion Delcroix</name><affiliation><nlm:affiliation>Gasthuisberg University Hospital, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Pulido, Tomas" sort="Pulido, Tomas" uniqKey="Pulido T" first="Tomás" last="Pulido">Tomás Pulido</name><affiliation><nlm:affiliation>Ignacio Chávez National Heart Institute, Mexico City, Mexico.</nlm:affiliation></affiliation></author><author><name sortKey="Simonneau, Gerald" sort="Simonneau, Gerald" uniqKey="Simonneau G" first="Gérald" last="Simonneau">Gérald Simonneau</name><affiliation><nlm:affiliation>Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France, and INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, France.</nlm:affiliation></affiliation></author><author><name sortKey="Wlodarczyk, John" sort="Wlodarczyk, John" uniqKey="Wlodarczyk J" first="John" last="Wlodarczyk">John Wlodarczyk</name><affiliation><nlm:affiliation>John Wlodarczyk Consulting Services, Newcastle, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Rubin, Lewis J" sort="Rubin, Lewis J" uniqKey="Rubin L" first="Lewis J" last="Rubin">Lewis J. Rubin</name><affiliation><nlm:affiliation>University of California, San Diego Medical School, San Diego, CA.</nlm:affiliation></affiliation></author><author><name sortKey="Jansa, Pavel" sort="Jansa, Pavel" uniqKey="Jansa P" first="Pavel" last="Jansa">Pavel Jansa</name><affiliation><nlm:affiliation>Charles University, Prague, Czech Republic.</nlm:affiliation></affiliation></author><author><name sortKey="Hunsche, Elke" sort="Hunsche, Elke" uniqKey="Hunsche E" first="Elke" last="Hunsche">Elke Hunsche</name><affiliation><nlm:affiliation>Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Galie, Nazzareno" sort="Galie, Nazzareno" uniqKey="Galie N" first="Nazzareno" last="Galiè">Nazzareno Galiè</name><affiliation><nlm:affiliation>Bologna University Hospital, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Perchenet, Loic" sort="Perchenet, Loic" uniqKey="Perchenet L" first="Loïc" last="Perchenet">Loïc Perchenet</name><affiliation><nlm:affiliation>Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Sitbon, Olivier" sort="Sitbon, Olivier" uniqKey="Sitbon O" first="Olivier" last="Sitbon">Olivier Sitbon</name><affiliation><nlm:affiliation>Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France, and INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27671974</idno><idno type="pmid">27671974</idno><idno type="doi">10.1016/j.chest.2016.08.1473</idno><idno type="wicri:Area/PubMed/Corpus">001375</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001375</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.</title><author><name sortKey="Mehta, Sanjay" sort="Mehta, Sanjay" uniqKey="Mehta S" first="Sanjay" last="Mehta">Sanjay Mehta</name><affiliation><nlm:affiliation>London Health Sciences Centre, Victoria Hospital, Western University, London, ON, Canada. Electronic address: sanjay.mehta@lhsc.on.ca.</nlm:affiliation></affiliation></author><author><name sortKey="Sastry, Bhagavatula Kutumba Srinivasa" sort="Sastry, Bhagavatula Kutumba Srinivasa" uniqKey="Sastry B" first="Bhagavatula Kutumba Srinivasa" last="Sastry">Bhagavatula Kutumba Srinivasa Sastry</name><affiliation><nlm:affiliation>CARE Hospitals, Hyderabad, India.</nlm:affiliation></affiliation></author><author><name sortKey="Souza, Rogerio" sort="Souza, Rogerio" uniqKey="Souza R" first="Rogério" last="Souza">Rogério Souza</name><affiliation><nlm:affiliation>Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Torbicki, Adam" sort="Torbicki, Adam" uniqKey="Torbicki A" first="Adam" last="Torbicki">Adam Torbicki</name><affiliation><nlm:affiliation>Centre of Postgraduate Medical Education, Europejskie Centrum Zdrowia, Otwock, Poland.</nlm:affiliation></affiliation></author><author><name sortKey="Ghofrani, Hossein Ardeschir" sort="Ghofrani, Hossein Ardeschir" uniqKey="Ghofrani H" first="Hossein-Ardeschir" last="Ghofrani">Hossein-Ardeschir Ghofrani</name><affiliation><nlm:affiliation>University of Giessen and Marburg Lung Center, Giessen, Germany, Member of the German Center of Lung Research (DZL), Giessen, Germany, and Department of Medicine, Imperial College London, London, England.</nlm:affiliation></affiliation></author><author><name sortKey="Channick, Richard N" sort="Channick, Richard N" uniqKey="Channick R" first="Richard N" last="Channick">Richard N. Channick</name><affiliation><nlm:affiliation>Massachusetts General Hospital, Boston, MA.</nlm:affiliation></affiliation></author><author><name sortKey="Delcroix, Marion" sort="Delcroix, Marion" uniqKey="Delcroix M" first="Marion" last="Delcroix">Marion Delcroix</name><affiliation><nlm:affiliation>Gasthuisberg University Hospital, Leuven, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Pulido, Tomas" sort="Pulido, Tomas" uniqKey="Pulido T" first="Tomás" last="Pulido">Tomás Pulido</name><affiliation><nlm:affiliation>Ignacio Chávez National Heart Institute, Mexico City, Mexico.</nlm:affiliation></affiliation></author><author><name sortKey="Simonneau, Gerald" sort="Simonneau, Gerald" uniqKey="Simonneau G" first="Gérald" last="Simonneau">Gérald Simonneau</name><affiliation><nlm:affiliation>Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France, and INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, France.</nlm:affiliation></affiliation></author><author><name sortKey="Wlodarczyk, John" sort="Wlodarczyk, John" uniqKey="Wlodarczyk J" first="John" last="Wlodarczyk">John Wlodarczyk</name><affiliation><nlm:affiliation>John Wlodarczyk Consulting Services, Newcastle, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Rubin, Lewis J" sort="Rubin, Lewis J" uniqKey="Rubin L" first="Lewis J" last="Rubin">Lewis J. Rubin</name><affiliation><nlm:affiliation>University of California, San Diego Medical School, San Diego, CA.</nlm:affiliation></affiliation></author><author><name sortKey="Jansa, Pavel" sort="Jansa, Pavel" uniqKey="Jansa P" first="Pavel" last="Jansa">Pavel Jansa</name><affiliation><nlm:affiliation>Charles University, Prague, Czech Republic.</nlm:affiliation></affiliation></author><author><name sortKey="Hunsche, Elke" sort="Hunsche, Elke" uniqKey="Hunsche E" first="Elke" last="Hunsche">Elke Hunsche</name><affiliation><nlm:affiliation>Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Galie, Nazzareno" sort="Galie, Nazzareno" uniqKey="Galie N" first="Nazzareno" last="Galiè">Nazzareno Galiè</name><affiliation><nlm:affiliation>Bologna University Hospital, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Perchenet, Loic" sort="Perchenet, Loic" uniqKey="Perchenet L" first="Loïc" last="Perchenet">Loïc Perchenet</name><affiliation><nlm:affiliation>Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Sitbon, Olivier" sort="Sitbon, Olivier" uniqKey="Sitbon O" first="Olivier" last="Sitbon">Olivier Sitbon</name><affiliation><nlm:affiliation>Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France, and INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Chest</title><idno type="eISSN">1931-3543</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Dose-Response Relationship, Drug</term><term>Drug Monitoring (methods)</term><term>Endothelin B Receptor Antagonists (administration & dosage)</term><term>Endothelin B Receptor Antagonists (adverse effects)</term><term>Female</term><term>Humans</term><term>Hypertension, Pulmonary (diagnosis)</term><term>Hypertension, Pulmonary (drug therapy)</term><term>Hypertension, Pulmonary (physiopathology)</term><term>Hypertension, Pulmonary (psychology)</term><term>Male</term><term>Middle Aged</term><term>Patient Acuity</term><term>Pyrimidines (administration & dosage)</term><term>Pyrimidines (adverse effects)</term><term>Quality of Life</term><term>Sulfonamides (administration & dosage)</term><term>Sulfonamides (adverse effects)</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Endothelin B Receptor Antagonists</term><term>Pyrimidines</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Endothelin B Receptor Antagonists</term><term>Pyrimidines</term><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hypertension, Pulmonary</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypertension, Pulmonary</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Monitoring</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Hypertension, Pulmonary</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Hypertension, Pulmonary</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Patient Acuity</term><term>Quality of Life</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pulmonary arterial hypertension (PAH) leads to reduced health-related quality of life (HRQoL). The objectives of this analysis were to evaluate the effect of macitentan on HRQoL in patients with PAH in the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome (SERAPHIN) study. The association between baseline HRQoL and long-term outcomes was also investigated.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27671974</PMID><DateCreated><Year>2016</Year><Month>09</Month><Day>27</Day></DateCreated><DateCompleted><Year>2017</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2017</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1931-3543</ISSN><JournalIssue CitedMedium="Internet"><Volume>151</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Chest</Title><ISOAbbreviation>Chest</ISOAbbreviation></Journal><ArticleTitle>Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.</ArticleTitle><Pagination><MedlinePgn>106-118</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0012-3692(16)59209-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.chest.2016.08.1473</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Pulmonary arterial hypertension (PAH) leads to reduced health-related quality of life (HRQoL). The objectives of this analysis were to evaluate the effect of macitentan on HRQoL in patients with PAH in the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hypertension to Improve Clinical Outcome (SERAPHIN) study. The association between baseline HRQoL and long-term outcomes was also investigated.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients were randomized to placebo, macitentan 3 mg, or macitentan 10 mg once daily. Patients aged 14 years or older completed the 36-Item Short Form Survey (SF-36) at baseline, at month 6 and month 12, and at the end of treatment (EOT). The absolute change from baseline to month 6 in SF-36 scores was calculated. The time to a clinically meaningful deterioration in the SF-36 physical component summary and mental component summary (PCS and MCS) scores and associations between baseline PCS/MCS scores and time to morbidity/mortality events were also assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At month 6, macitentan 10 mg significantly improved seven of eight SF-36 domains and the PCS and MCS scores vs placebo. Macitentan 10 mg significantly reduced the risk of a three-point or greater deterioration in PCS (hazard ratio [HR], 0.60; 95% CI, 0.47-0.76; P < .0001) and MCS scores (HR, 0.76; 95% CI, 0.61-0.95; P = .0173) until EOT vs placebo. Patients with a baseline PCS score greater than the median baseline value had a significantly reduced risk of morbidity/mortality compared with patients with a PCS score less than the median; a similar result was observed for the MCS score.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Macitentan significantly improved HRQoL in patients with PAH compared with placebo and significantly reduced the risk of a clinically meaningful HRQoL deterioration. An association between better baseline HRQoL and improved long-term outcomes was shown.</AbstractText><AbstractText Label="TRIAL REGISTRY" NlmCategory="BACKGROUND">ClinicalTrials.gov; No.: NCT00660179; URL: clinicaltrials.gov.</AbstractText><CopyrightInformation>Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre, Victoria Hospital, Western University, London, ON, Canada. Electronic address: sanjay.mehta@lhsc.on.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sastry</LastName><ForeName>Bhagavatula Kutumba Srinivasa</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>CARE Hospitals, Hyderabad, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Souza</LastName><ForeName>Rogério</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torbicki</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre of Postgraduate Medical Education, Europejskie Centrum Zdrowia, Otwock, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghofrani</LastName><ForeName>Hossein-Ardeschir</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>University of Giessen and Marburg Lung Center, Giessen, Germany, Member of the German Center of Lung Research (DZL), Giessen, Germany, and Department of Medicine, Imperial College London, London, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Channick</LastName><ForeName>Richard N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delcroix</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Gasthuisberg University Hospital, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pulido</LastName><ForeName>Tomás</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Ignacio Chávez National Heart Institute, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simonneau</LastName><ForeName>Gérald</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France, and INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wlodarczyk</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>John Wlodarczyk Consulting Services, Newcastle, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubin</LastName><ForeName>Lewis J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>University of California, San Diego Medical School, San Diego, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansa</LastName><ForeName>Pavel</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Charles University, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hunsche</LastName><ForeName>Elke</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galiè</LastName><ForeName>Nazzareno</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Bologna University Hospital, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perchenet</LastName><ForeName>Loïc</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sitbon</LastName><ForeName>Olivier</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; Université Paris-Sud, Laboratoire d'Excellence en Recherche sur le Médicament et Innovation Thérapeutique, Le Kremlin-Bicêtre, France, and INSERM U-999, Centre chirurgical Marie Lannelongue, Le Plessis Robinson, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00660179</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Chest</MedlineTA><NlmUniqueID>0231335</NlmUniqueID><ISSNLinking>0012-3692</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065131">Endothelin B Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011743">Pyrimidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>Z9K9Y9WMVL</RegistryNumber><NameOfSubstance UI="C533860">macitentan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016903" MajorTopicYN="N">Drug Monitoring</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065131" MajorTopicYN="N">Endothelin B Receptor Antagonists</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="Y">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D062072" MajorTopicYN="N">Patient Acuity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011743" MajorTopicYN="Y">Pyrimidines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="Y">Sulfonamides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">health-related quality of life</Keyword><Keyword MajorTopicYN="Y">pharmacotherapy</Keyword><Keyword MajorTopicYN="Y">pulmonary arterial hypertension</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>02</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>07</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>08</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27671974</ArticleId><ArticleId IdType="pii">S0012-3692(16)59209-5</ArticleId><ArticleId IdType="doi">10.1016/j.chest.2016.08.1473</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001375 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001375 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27671974
|texte= Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension: Results From the Randomized Controlled SERAPHIN Trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27671974" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |